Stay updated on iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.

Latest updates to the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page
- Check2 days agoChange DetectedRevision history updated to include v3.5.2 and remove v3.5.0.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedUpdated the page’s revision tag from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. No user-facing content or study information appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1; no substantive study details, outcomes, or eligibility information appear to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page now shows a glossary toggle, updates the QC label from 'Last Update' to 'Last Update Submitted that Met QC Criteria', standardizes the No FEAR Act Data wording, and updates the revision from v3.3.4 to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.